Skip to main content

19 August 2021

Gene therapy: lentivirus

Download PDF – 7.2 MB

OXGENE helps solve the challenge of scalable manufacture for gene therapy. We have redeveloped the lentiviral plasmid system, resulting in yields greater than 1×10⁸ TU/ml. We have also generated manufacture-ready, suspension-mode lentiviral packaging cell lines to facilitate large scale lentiviral production.

Our technologies maximise process reproducibility and minimise manufacturing costs for some of the industry’s most exciting therapies.

Resource updated on 23/06/2022

Download the resource to continue reading.